Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Truist Financial Corp

Truist Financial Corp decreased its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 40.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,193 shares of the biopharmaceutical company's stock after selling 59,003 shares during the period. Truist Financial Corp owned 0.16% of Emergent BioSolutions worth $814,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stifel Financial Corp acquired a new position in Emergent BioSolutions in the 3rd quarter valued at about $96,000. FORA Capital LLC purchased a new position in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $103,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Emergent BioSolutions during the third quarter worth approximately $141,000. Entropy Technologies LP acquired a new stake in shares of Emergent BioSolutions during the third quarter worth $155,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in Emergent BioSolutions in the 3rd quarter valued at $295,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Price Performance

NYSE EBS traded down $0.60 during mid-day trading on Wednesday, hitting $5.80. The stock had a trading volume of 1,791,073 shares, compared to its average volume of 2,669,735. The company has a 50 day simple moving average of $9.43 and a 200 day simple moving average of $9.02. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a market cap of $314.00 million, a price-to-earnings ratio of -1.41 and a beta of 1.62. Emergent BioSolutions Inc. has a 52-week low of $1.82 and a 52-week high of $15.10.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. During the same quarter in the previous year, the company posted ($0.77) EPS. Equities analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on EBS. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday. Finally, Benchmark increased their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.